Last updated: August 4, 2026
Impax Laboratories sued Actavis Laboratories FL in the U.S. District Court for the District of New Jersey after Actavis filed an abbreviated new drug application seeking approval for a generic version of Rytary, Impax’s extended-release carbidopa/levodopa product. The case was a Hatch-Waxman patent action involving Impax’s multiparticulate extended-release formulation technology. The asserted patents covered the drug’s formulation and release profile rather than the underlying carbidopa or levodopa molecules.
What drug was involved in Impax Laboratories v. Actavis?
The litigation concerned Rytary, an extended-release oral capsule containing carbidopa and levodopa.
| Item |
Information |
| Brand |
Rytary |
| Active ingredients |
Carbidopa and levodopa |
| Dosage form |
Extended-release capsules |
| NDA holder at launch |
Impax Laboratories, Inc. |
| FDA approval |
Jan. 7, 2015 |
| NDA |
NDA 207,927 |
| Therapeutic category |
Parkinson’s disease and parkinsonism |
| Regulatory pathway challenged |
ANDA under the Hatch-Waxman Act |
| Defendant |
Actavis Laboratories FL, Inc. |
| Court |
U.S. District Court for the District of New Jersey |
| Civil action |
No. 2:15-cv-06934 |
Rytary uses a combination of immediate-release and extended-release drug particles. The formulation is designed to provide an initial levodopa exposure followed by sustained delivery. The formulation differs from conventional immediate-release carbidopa/levodopa products such as Sinemet.
What patents did Impax assert against Actavis?
Impax’s complaint asserted patents directed to Rytary’s multiparticulate extended-release composition and related formulation characteristics. The principal patents associated with the action were U.S. Patent Nos. 8,741,929 and 8,846,100.
| Patent |
General subject matter |
Relevance to Rytary |
| U.S. Patent No. 8,741,929 |
Multiparticulate modified-release compositions |
Covered formulation architecture and release behavior |
| U.S. Patent No. 8,846,100 |
Extended-release multiparticulate compositions |
Covered additional formulation and release-profile limitations |
The asserted claims did not depend on patent protection for carbidopa or levodopa as chemical entities. The commercial significance came from formulation protection. This distinction matters because an ANDA applicant could not avoid infringement merely by using the same active ingredients in a different dosage form if its proposed product practiced the asserted formulation claims.
Patent scope depended on the claim limitations, including particle populations, release characteristics, and the relationship between immediate-release and extended-release components. The infringement analysis therefore required review of Actavis’s proposed product and its ANDA certifications, not only a comparison of active ingredients.
Why did Actavis face a patent lawsuit?
Actavis’s ANDA filing included a Paragraph IV certification challenging Impax’s listed patents. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product.
Impax responded by filing suit within the statutory period. The filing triggered the Hatch-Waxman litigation framework and imposed an automatic 30-month stay of FDA approval, subject to statutory exceptions and court action.
The dispute had three principal legal questions:
- Whether Actavis’s proposed generic formulation would infringe the asserted claims.
- Whether the asserted claims were invalid for anticipation or obviousness.
- Whether Impax’s patents were enforceable and properly listed for the product.
The case was therefore a formulation patent dispute, not a simple active-ingredient patent challenge.
What was the procedural history of the case?
The action was filed in 2015 in the District of New Jersey. The case proceeded as an ANDA litigation involving Impax as plaintiff and Actavis as the generic applicant.
Procedural timeline
| Date |
Event |
| Jan. 7, 2015 |
FDA approved Rytary |
| 2015 |
Actavis filed an ANDA challenging Rytary-related patent protection |
| 2015 |
Impax filed Civil Action No. 2:15-cv-06934 |
| 2015-2017 |
Claim construction, discovery, and pretrial patent proceedings |
| Later proceedings |
The docket reflects resolution of the dispute without a reported merits decision establishing a final appellate infringement or invalidity rule for the asserted patents |
The case should not be confused with later Rytary-related patent disputes involving other ANDA applicants or later-issued patents. Patent scope and launch timing must be assessed by applicant, ANDA, patent family, and settlement agreement.
Was there a Paragraph IV challenge to Rytary?
Yes. The action arose from Actavis’s Paragraph IV challenge to Rytary-related patent protection.
A Paragraph IV filing does not establish that the generic will launch. It creates a litigation pathway. The reference drug company can obtain a 30-month approval stay, but the eventual launch date depends on the outcome of the litigation, settlement terms, patent expiration, pediatric exclusivity, and any contractual launch provisions.
The commercial effect of the challenge was to place Rytary’s formulation patents at risk before the patents’ ordinary expiration dates. Because Rytary was a formulation-driven product, the strength of the case depended on the breadth and validity of the formulation claims.
What was the Orange Book status of Rytary?
Rytary’s protection included Orange Book-listed patents directed to the drug product and its formulation. The Orange Book listing is relevant because it determines the patents that an ANDA applicant must address through Paragraph III or Paragraph IV certification.
Orange Book analysis
Orange Book-listed Rytary patents generally fell into these categories:
- Formulation patents covering multiparticulate extended-release compositions.
- Drug-product patents covering the approved extended-release capsule.
- Later-issued patents covering additional formulation or product characteristics.
The Orange Book does not list every patent that may affect commercial entry. Unlisted patents, process patents, contractual restrictions, regulatory exclusivity, and patent settlements can also affect launch risk. An Orange Book patent listing is a regulatory signal, not a final determination of infringement or validity.
When does Rytary lose exclusivity?
Rytary’s market protection is based on several separate rights:
| Protection |
Practical effect |
| New chemical entity exclusivity |
Not the principal protection for Rytary because carbidopa and levodopa were previously approved active ingredients |
| New drug exclusivity |
Applied to the FDA approval of the new product, subject to the NDA’s regulatory history |
| Orange Book patents |
Can delay or restrict ANDA approval and commercial launch |
| Pediatric exclusivity |
May add six months to qualifying patent and exclusivity periods |
| Settlement rights |
May establish an agreed generic launch date earlier than patent expiry |
| Later formulation patents |
Can create additional litigation or launch exposure |
The earliest legally permissible generic launch date cannot be determined from the district-court case number alone. It depends on the operative Orange Book listings, any final patent judgments, and the terms of any settlement or license involving Actavis.
Did the case produce a reported invalidity or infringement ruling?
No reported final merits decision from this docket should be treated as establishing that all Rytary patents were either valid and infringed or invalid and not infringed.
That distinction is important for diligence. A docket termination, settlement, consent order, or dismissal does not have the same analytical effect as a final judgment following trial. A settlement generally leaves patent validity and infringement legally unresolved unless the parties’ agreement or a court order states otherwise.
For investment or launch modeling, the relevant documents are:
- The complaint and asserted patent list.
- Actavis’s ANDA certifications.
- Claim-construction orders.
- Any stipulation narrowing the claims or patents at issue.
- The dismissal or termination order.
- The settlement agreement, if filed or publicly disclosed.
- Current FDA Orange Book listings.
What litigation affected generic Rytary entry?
The Actavis case was one part of the broader Rytary patent landscape. Generic-entry risk can arise from several types of litigation:
Formulation patent litigation
Formulation patents are the central risk because they may cover the release profile and particle design used in the commercial product. A generic applicant may seek to design around particular claim limitations, but changes to release characteristics can affect bioequivalence and FDA approval.
Method-of-use patents
Rytary is approved for Parkinson’s disease and parkinsonism. Method-of-use patents may create additional litigation if they are listed for the product and the ANDA applicant uses a section viii statement to carve out protected indications. The feasibility of a carve-out depends on the patent claims, the proposed label, and whether the remaining label still encourages infringement.
Manufacturing and process patents
Process patents generally are not listed in the Orange Book, but they can still affect manufacturing strategy. A generic applicant may avoid a process patent through a different manufacturing route, although the alternative process must produce a product that meets the ANDA specifications and bioequivalence requirements.
Later applicants
The existence of an Actavis dispute does not establish the outcome for later generic applicants. Each applicant may use different formulation parameters, certifications, litigation defenses, and settlement terms.
How strong was Impax’s patent estate?
Impax’s patent position was stronger than a single active-ingredient patent estate because it relied on several layers of product protection:
- The Rytary product used a differentiated extended-release formulation.
- The asserted patents targeted formulation structure and release performance.
- The patents were relevant to the approved dosage form.
- A generic formulation that closely replicated Rytary’s pharmacokinetic profile could face infringement exposure.
The estate also had limitations:
- Formulation claims can be vulnerable to obviousness attacks based on known extended-release technologies.
- Multiparticulate systems may have prior-art references disclosing similar particle designs and release mechanisms.
- Narrow claim limitations can permit a design-around.
- A Paragraph IV challenger can separate FDA approval from commercial launch by using a different formulation or seeking a label carve-out.
- Patent expiry and settlement terms can have greater commercial importance than litigation merits.
The practical strength of the estate was therefore moderate to strong for a close formulation copy, but less certain against a technically differentiated product.
What generic launch scenarios existed for Actavis?
Actavis’s launch possibilities depended on the litigation outcome and any agreement with Impax.
| Scenario |
Effect on Rytary |
| Impax wins on infringement and validity |
Actavis approval or launch could be delayed until patent expiry or a licensed date |
| Actavis wins on noninfringement |
FDA approval could proceed after statutory and regulatory barriers were resolved |
| Actavis invalidates the patents |
Entry could occur before ordinary patent expiry, subject to other listed patents |
| Settlement with licensed entry |
Actavis could launch on an agreed date, often before full patent expiry |
| Design-around |
Actavis could pursue approval for a non-infringing formulation, subject to FDA requirements |
| Case dismissal without public merits judgment |
Commercial timing would depend primarily on settlement and remaining patent rights |
A first-filer advantage could also affect market entry if Actavis was the first ANDA applicant to submit a qualifying Paragraph IV certification. That issue requires review of FDA records and the specific ANDA sequence.
Did Impax license Rytary rights to Actavis?
The public case record does not provide a reported merits judgment establishing the commercial terms of any license or settlement between Impax and Actavis. A settlement may have resolved the lawsuit without adjudicating the asserted patents.
For transaction analysis, the critical terms would include:
- Authorized generic rights.
- Earliest permitted launch date.
- Geographic limits.
- Dosage strengths covered.
- Restrictions on formulation changes.
- Acceleration clauses if another generic enters.
- Patent challenge waivers.
- Covenants not to sue.
- Royalty or supply obligations.
- Treatment of later-issued patents.
A settlement launch date is not equivalent to patent expiry. It is a contractual permission that may be subject to conditions and subsequent patent developments.
What was the FDA regulatory status of Rytary?
The FDA approved Rytary in January 2015 as an extended-release carbidopa/levodopa capsule. Approval established the reference product for ANDA applicants.
FDA approval of a generic Rytary product would require, among other elements:
- Pharmaceutical equivalence.
- Bioequivalence.
- Compliance with current good manufacturing practices.
- An acceptable label.
- Resolution of applicable patent and exclusivity barriers.
The FDA does not resolve all patent questions through the ANDA review process. Patent validity and infringement are generally litigated in federal court under the Hatch-Waxman framework.
How does Rytary patent protection compare with Sinemet?
| Issue |
Rytary |
Sinemet |
| Active ingredients |
Carbidopa/levodopa |
Carbidopa/levodopa |
| Release profile |
Extended release |
Immediate release and other formulations depending on product |
| Primary protection |
Formulation and product patents |
Legacy product and formulation rights |
| Generic risk |
Requires bioequivalent extended-release formulation |
More mature generic market |
| Litigation focus |
Multiparticulate release technology |
Product-specific formulation, labeling, and method claims |
| Commercial differentiation |
Duration and dosing profile |
Established immediate-release therapy |
Rytary’s competitive protection depended more heavily on formulation performance than on chemical-entity exclusivity. That structure creates a narrower but commercially meaningful barrier to entry.
What revenue exposure did the litigation create?
Rytary represented a key commercial product for Impax after its 2015 launch. Generic entry could affect:
- Net sales of Rytary capsules.
- Gross margin.
- Prescriber conversion and patient retention.
- Rebates and payer positioning.
- License and royalty economics.
- Impax’s valuation before its combination with Amneal Pharmaceuticals.
The revenue impact would depend on whether a generic entered as an authorized generic, an independently marketed ANDA product, or a competing extended-release formulation. A single generic entrant typically produces less immediate price erosion than multiple entrants, but extended-release products can experience substantial share loss if the generic is therapeutically substitutable and broadly covered by payers.
Key Takeaways
- The case concerned Actavis’s Paragraph IV challenge to Impax’s Rytary formulation patents.
- Rytary contains extended-release carbidopa and levodopa capsules.
- The principal asserted patents were U.S. Patent Nos. 8,741,929 and 8,846,100.
- The dispute focused on multiparticulate extended-release formulation technology, not new-molecule protection.
- The docket should not be characterized as establishing a final merits ruling on patent validity or infringement.
- Generic-entry timing depended on the litigation disposition, Orange Book listings, FDA exclusivity, and any settlement or license.
- Rytary’s commercial exposure was tied to formulation substitution and the number and timing of ANDA entrants.
- Later-issued Rytary patents and separate generic litigation must be analyzed independently from Civil Action No. 2:15-cv-06934.
FAQs About Impax Laboratories v. Actavis Laboratories FL
What was the case number for the Rytary patent litigation?
The case was Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc., No. 2:15-cv-06934, in the U.S. District Court for the District of New Jersey.
What type of FDA filing triggered the lawsuit?
Actavis filed an ANDA containing a Paragraph IV certification challenging patents associated with Rytary.
Were carbidopa and levodopa themselves patented in the case?
No. The dispute centered on extended-release formulation technology and the Rytary dosage form rather than exclusive rights to the underlying active ingredients.
Can a generic receive FDA approval before Rytary patent expiry?
Yes, depending on the applicable 30-month stay, regulatory exclusivity, patent certifications, litigation outcome, settlement terms, and whether the proposed product avoids or defeats the relevant patent claims.
Does dismissal prove that Actavis defeated Impax’s patents?
No. A dismissal or settlement without a final merits judgment does not establish that the patents were invalid or not infringed.
References
-
U.S. District Court for the District of New Jersey. (2015). Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc., No. 2:15-cv-06934, docket records.
-
U.S. Food and Drug Administration. (2015). FDA approves Rytary extended-release capsules for Parkinson’s disease. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,741,929: Multiparticulate modified-release compositions. USPTO.
-
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,846,100: Multiparticulate modified-release compositions. USPTO.
-
21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.
-
35 U.S.C. § 271(e)(2). Patent infringement relating to regulatory submissions.
